US FDA approves expanded use of Lilly's bowel disease drug
Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment
Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.
FDA approves first new schizophrenia drug in more than 30 years
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
FDA approves new drug for advanced Parkinson’s Disease
Thousands of Americans are diagnosed every year with Parkinson’s Disease. It’s a movement disorder that affects the central nervous system. Tremor is a common symptom. The Food and Drug Administration recently approved a new drug for those living with advanced Parkinson’s.
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
Lilly gets FDA approval for Omvoh for Crohn's disease
Eli Lilly (NYSE:LLY) has received FDA approval for its drug Omvoh, also known as mirikizumab-mrkz, for the treatment of moderately to severely active Crohn's disease in adults. The drug was previously approved in 2023 for the treatment of moderately to severely active ulcerative colitis in adults.
thecardiologyadvisor.com1d
2024 Novel Drug and Biological Product Approvals
The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.
verywellhealth1d
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
DC Circuit Skeptical of FDA Rejection of Vanda’s Jet Lag Drug
The FDA met resistance from a three-judge panel Wednesday over its decision to refuse approval of Vanda Pharmaceuticals ...
FiercePharma2d
JPM25: BridgeBio's cardiomyopathy drug is off to a roaring start
Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, ...